From April 1, 2021 to June 30, 2021, the company has repurchased 13,300,125 shares, representing 2.35% for CNY 129.45 million. With this, the company has completed the repurchase of 16,199,425 shares, representing 2.86% for CNY 154.67 million under the buyback announced on February 2, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25.86 CNY | +0.62% | -3.33% | +51.14% |
05-13 | Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug | MT |
04-25 | Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+51.14% | 2.02B | |
+44.36% | 6.34B | |
-13.52% | 4.61B | |
+10.85% | 3.39B | |
-6.52% | 3.29B | |
-0.71% | 2.58B | |
-5.22% | 1.73B | |
+1.29% | 1.67B | |
+57.69% | 1.63B | |
-9.67% | 1.59B |
- Stock Market
- Equities
- 600285 Stock
- News Henan Lingrui Pharmaceutical Co., Ltd.
- Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.